Tom H M Ottenhoff Selected Research

Interferon-gamma (Interferon, gamma)

1/2020	Systemic and pulmonary C1q as biomarker of progressive disease in experimental non-human primate tuberculosis.
7/2019	Radiological Signs of Latent Tuberculosis on Chest Radiography: A Systematic Review and Meta-Analysis.
1/2018	A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis.
10/2016	Multifunctional T Cell Response to DosR and Rpf Antigens Is Associated with Protection in Long-Term Mycobacterium tuberculosis-Infected Individuals in Colombia.
8/2012	Risk factors associated with indeterminate gamma interferon responses in the assessment of latent tuberculosis infection in a high-incidence environment.
1/2012	Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area.
11/2009	Genetic deficiencies of innate immune signalling in human infectious disease.
3/2008	Rational combination of peptides derived from different Mycobacterium leprae proteins improves sensitivity for immunodiagnosis of M. leprae infection.
7/2007	Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation.
2/2007	Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tom H M Ottenhoff Research Topics

Disease

120	Tuberculosis (Tuberculoses) 05/2022 - 05/2002
91	Infections 05/2022 - 09/2002
17	Leprosy (Hansen's Disease) 11/2019 - 12/2002
13	Pulmonary Tuberculosis 01/2018 - 02/2007
12	Latent Tuberculosis 01/2021 - 03/2012
11	Inflammation (Inflammations) 05/2022 - 06/2004
9	Communicable Diseases (Infectious Diseases) 10/2018 - 07/2002
8	HIV Infections (HIV Infection) 01/2016 - 02/2010
6	Latent Infection 09/2015 - 02/2006
5	Disease Progression 01/2022 - 01/2006
5	Neoplasms (Cancer) 01/2022 - 01/2005
4	Coinfection 01/2022 - 01/2006
4	Lung Diseases (Lung Disease) 01/2020 - 09/2005
4	Paucibacillary Leprosy 12/2012 - 09/2005
3	Vesicular Stomatitis 01/2022 - 12/2017
3	Persistent Infection 06/2009 - 03/2004
3	Hypoxia (Hypoxemia) 07/2007 - 07/2006
2	COVID-19 04/2022 - 01/2022
2	Fever (Fevers) 01/2021 - 01/2017
2	Bacterial Infections (Bacterial Infection) 01/2021 - 01/2021
2	Malaria 10/2019 - 10/2016
2	Cicatrix (Scar) 05/2019 - 01/2012
2	Autoimmune Diseases (Autoimmune Disease) 01/2017 - 03/2006
2	Salmonella Infections (Salmonellosis) 04/2006 - 01/2006
1	Type 2 Diabetes Mellitus (MODY) 12/2019

Drug/Important Bio-Agent (IBA)

59	AntigensIBA 06/2021 - 05/2002
45	VaccinesIBA 05/2022 - 12/2002
33	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2009
31	Proteins (Proteins, Gene)FDA Link 04/2022 - 12/2002
26	CytokinesIBA 05/2022 - 07/2002
17	Interferon-gamma (Interferon, gamma)IBA 01/2020 - 09/2002
15	Tuberculin (PPD)IBA 01/2020 - 12/2002
12	Peptides (Polypeptides)IBA 01/2022 - 05/2005
11	AntibodiesIBA 01/2022 - 03/2008
11	Mycobacterium tuberculosis antigensIBA 06/2021 - 08/2009
11	Interleukin-12 (IL 12)IBA 12/2019 - 07/2002
9	RNA (Ribonucleic Acid)IBA 12/2020 - 05/2014
9	InterferonsIBA 01/2020 - 01/2012
7	BCG Vaccine FDA Link 01/2019 - 01/2006
6	Interleukin-6 (Interleukin 6)IBA 05/2022 - 11/2008
6	Pharmaceutical PreparationsIBA 01/2022 - 03/2008
5	Immunoglobulin G (IgG)IBA 04/2022 - 09/2010
5	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 04/2004
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2010 - 12/2002
4	Complement System Proteins (Complement)IBA 01/2020 - 07/2007
4	Interleukin-17 (Interleukin 17)IBA 01/2017 - 03/2006
4	EpitopesIBA 01/2014 - 06/2004
3	GoldIBA 01/2022 - 01/2011
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 05/2009
3	Interleukin-10 (Interleukin 10)IBA 01/2019 - 12/2002
3	Immunoglobulin A (IgA)IBA 01/2019 - 02/2016
3	DNA VaccinesIBA 01/2018 - 04/2004
3	AerosolsIBA 05/2017 - 03/2004
3	C-Reactive ProteinIBA 01/2016 - 01/2009
3	Pattern Recognition ReceptorsIBA 02/2015 - 11/2005
3	Interleukin-23 (Interleukin 23)IBA 11/2009 - 03/2003
3	Recombinant ProteinsIBA 08/2009 - 11/2003
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2007 - 07/2006
2	Immunoglobulins (Immunoglobulin)IBA 04/2022 - 10/2018
2	Glycoproteins (Glycoprotein)IBA 01/2022 - 01/2021
2	ChemokinesIBA 01/2021 - 01/2016
2	LipidsIBA 01/2019 - 06/2018
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2018 - 09/2015
2	Messenger RNA (mRNA)IBA 09/2015 - 01/2015
2	Liposomes (Liposome)IBA 12/2014 - 12/2011
2	Tuberculosis VaccinesIBA 01/2014 - 01/2009
2	Interferon Type IIBA 05/2013 - 01/2012
2	GlycolipidsIBA 10/2011 - 03/2008
2	3' Untranslated Regions (3' UTR)IBA 12/2009 - 10/2007
2	Interferon gamma ReceptorIBA 09/2007 - 02/2007
2	HLA Antigens (Human Leukocyte Antigens)IBA 06/2006 - 01/2005
2	InterleukinsIBA 04/2006 - 12/2002
2	EnzymesIBA 03/2006 - 05/2005
1	Epidermal Growth Factor (EGF)IBA 05/2022
1	Antigen-Antibody Complex (Immune Complex)IBA 04/2022
1	bedaquiline (R207910)IBA 01/2022
1	Rifampin (Rifampicin)FDA LinkGeneric 01/2022
1	Hepatitis B e AntigensIBA 01/2022
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2022
1	Adenosine DeaminaseIBA 01/2021
1	Interleukin-22 (IL-22)IBA 01/2021
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	Pyruvate Dehydrogenase Acetyl-Transferring KinaseIBA 01/2021
1	Pyruvic Acid (Pyruvate)IBA 01/2021
1	CreatineIBA 01/2020
1	NAD (NADH)IBA 01/2020
1	Phosphocreatine (Neoton)IBA 01/2020
1	Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)IBA 01/2020
1	Glutathione (Reduced Glutathione)IBA 01/2020
1	Interleukin-15 (Interleukin 15)IBA 11/2019

Therapy/Procedure

18	Therapeutics 01/2022 - 01/2006
6	Resuscitation 03/2014 - 01/2009
4	Ligation 10/2018 - 09/2015
3	Immunotherapy 01/2021 - 01/2018
2	Highly Active Antiretroviral Therapy (HAART) 10/2018 - 01/2016
2	Drug Therapy (Chemotherapy) 01/2016 - 09/2010
1	Traction 01/2022
1	Duration of Therapy 01/2022
1	Aftercare (After-Treatment) 11/2019